Luis Raez, MD, FACP, FCCP, Memorial Cancer Institute/Memorial Healthcare System, Miami, FL, provides a summary of the lung cancer session at PRIMO 2024, highlighting updates on small cell lung cancer (SCLC) and immunotherapy. He reviews trials demonstrating the efficacy of neoadjuvant immunotherapy in improving survival outcomes and discusses ongoing research into potential markers for SCLC subtypes. Additionally, Dr Raez shares insights into promising targeted therapies, including a ROS1 inhibitor, and presents compelling evidence for its efficacy in patients with ROS1 mutations. He also discusses the evolving landscape of treatment options for EGFR-mutated lung cancer, including the potential addition of bispecific TKIs as a new frontline option. This interview took place at the 2024 PRIMO meeting in Honolulu, Hawaii.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.